Please Wait
Applying Filters...
menu
    • menu
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 224Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    30/12/2024 Aurobindo Pharma Limited
    India
    		 Aurobindo Pharma Limited 227MF10029 Entacapone 2015-01-23 2015-11-20 Plot No. 2, Maitrivihar, Ameerpet, Hyderabad Andhra Pradesh, India
    30/12/2024 Dipharma
    Italy
    		 Dipharma Francis S. r. l. 227MF10070 Entacapone 2015-03-12 2015-03-12 Via Bissone, 5, 20021-Baranzate, Milano, Italy